Renal Biomarkers Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

Renal Biomarkers Market Analysis

The renal biomarkers market is expected to register a CAGR of 7.76% during the forecast period.

Due to the COVID-19 pandemic, the footfall in hospitals and diagnostic centers initially decreased significantly, and many studies reported that people with comorbidity had higher chances of contracting severe COVID-19, which further led to a decrease in the tests and treatment procedures for kidney diseases. For instance, according to a research study published in January 2022, by Brogan M. et, al., patients with severe chronic kidney disease (CKD) had a higher mortality rate than those without CKD, and approximately half survived after 28 days. Thus, during the pandemic, the studied market was severely impacted. However, since the lockdown restrictions were lifted, the market has been recovering well. The emergence of COVID-19 led to new research in the area of biomarkers for the detection of the severity of COVID-19 in patients, which is further anticipated to augment the market's growth as new investments will be made in the area of research and development of renal biomarkers. For instance, in May 2021, a study was published in the Scientific Reports Journal that demonstrated the role of urine biomarkers in predicting mortality in SARS-CoV-2 infected patients. These ongoing studies have spurred research in this space for the discovery of novel biomarkers, which are expected to augment market growth.

The key factors propelling the growth of this market are the rising prevalence of various kidney-related diseases, the high prevalence of diabetes and high blood pressure, which are the leading causes of renal diseases, and rapid technological advancements in the field of genetics. According to the article published in Kidney International Supplements in April 2022, approximately 10% of the global population suffers from chronic kidney disease, and millions die each year. The rate of patients with chronic kidney disease is increasing. Additionally, the risk of diabetes-related chronic kidney diseases was much higher in Asian countries than in Western countries. For instance, according to the International Diabetes Federation report published in 2021, the estimated number of diabetes patients in 2021 was 74,194.7 thousand, and the number is expected to reach 92,973.7 thousand by 2030 in India. Thus, the growing prevalence of kidney diseases and their relative causes is expected to increase demand for their diagnosis, thereby boosting the growth of the biomarkers over the forecast period.

Advancements in the field of genetic technology during the last decade have enlightened people's knowledge regarding genetic regulatory pathways related to renal biomarkers. Due to rapid advances in genomic technologies, genetic analysis has become essential in clinical practice and research. Moreover, with the development of computer technology, renal biomarker testing has become widely accessible and feasible to perform, even in small-sized laboratories. Recent advances in genetics have created opportunities to study kidney disease on a variety of platforms applied to human populations. Renal biomarkers can also be integrated into genetic-level technological advancements for detecting, diagnosing, and treating kidney diseases. These rapid advances in genetics led to the development of more advanced renal biomarkers for treating kidney diseases, which ultimately drove the market.

Additionally, strategic activities by market players, such as partnerships, mergers and acquisitions, and product launches, are expected to propel the market's growth. For instance, in April 2021, Renalytix AI expanded its collaboration with the Joslin Diabetes Center to include new biomarkers for kidney disease found by the center's researchers in the company's KidneyIntelX platform. In February 2021, BioMerieux announced the CE marking of an innovative NEPHROCHECK assay to detect kidney stress in patients at risk of acute kidney injury (AKI).

Thus, due to the aforementioned factors, such as the growing burden of kidney diseases and strategic activities by market players, the renal biomarkers market is expected to grow at a significant rate during the forecast period. However, regulatory and reimbursement system issues may hamper the market's growth over the forecast period.

Renal Biomarkers Industry Segmentation

As per the scope of the report, renal biomarkers are biomarkers that help diagnose or identify patients at risk of developing kidney diseases by measuring their blood or urine levels. They are commonly released in acute or chronic kidney injuries, which are characterized by the rapid or gradual loss of kidney function resulting in serious clinical implications. The Renal Biomarkers Market is Segmented by Biomarker Type (Functional Biomarker, Up-regulated Protein, and Other Biomarker Types), Diagnostic Technique (Enzyme-linked Immunosorbent Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), and Liquid Chromatography-mass Spectrometry (LS-MS)), End User (Hospitals, Diagnostic Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Renal Biomarkers Market Trends

This section covers the major market trends shaping the Renal Biomarkers Market according to our research experts:

Serum Creatinine from Functional Biomarker is Expected to Hold a Significant Market Share

To understand key trends, Download Sample Report